Research programme: cancer vaccines - Aventis Pasteur/PDL BioPharmaAlternative Names: Cancer vaccines research programme - sanofi pasteur/Protein Design Labs
Latest Information Update: 17 Mar 2009
At a glance
- Originator sanofi pasteur
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 30 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form Sanofi-Aventis